Skip to main content
profile image
Selected Works of Pearl Kwong, MD, PhD, FAAD
Article
Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
JAMA Dermatology (2020)
  • Lawrence F Eichenfield, University of California, San Diego
  • Lawrence F Eichenfield, Boston Children's Hospital
  • Wendy McFalda, Clarkston Skin Research, Clarkston, Michigan.
  • Bradford Brabec, Midwest Children's Health Research Institute, Lincoln, Nebraska.
  • Elaine Siegfried, Saint Louis University
  • Pearl Kwong, Solutions Through Advanced Research, Jacksonville, Florida.
  • Mark McBride, Instat Consulting, Inc, Chatham, New Jersey.
  • Jayson Rieger, Verrica Pharmaceuticals Inc, West Chester, Pennsylvania.
  • Cynthia Willson, Verrica Pharmaceuticals Inc, West Chester, Pennsylvania.
  • Matthew Davidson, Verrica Pharmaceuticals Inc, West Chester, Pennsylvania.
  • Patrick Burnett, Verrica Pharmaceuticals Inc, West Chester, Pennsylvania.
Link
Disciplines
Publication Date
December 1, 2020
DOI
10.1001/JAMADERMATOL.2020.3238
Citation Information
Lawrence F Eichenfield, Lawrence F Eichenfield, Wendy McFalda, Bradford Brabec, et al.. "Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials." JAMA Dermatology Vol. 156 Iss. 12 (2020) p. 1315 - 1323
Available at: http://works.bepress.com/pearl-kwong/2/